Lobe Sciences Ltd. (CVE:LOBE) | Finanzwire

Basculer en Français

10281	Companies
212882	Keywords
142667	Articles
112725	Press releases

Home
Companies
Lobe Sciences Ltd.

BRIEF

published on 04/23/2026 at 14:05, 3 days 4 hours ago

Lobe Sciences Welcomes White House Order on Neurological Drug Development

Drug Development Neurological Disorders Research Expansion Executive Order Lobe Sciences
PRESS RELEASE

published on 04/23/2026 at 14:00, 3 days 4 hours ago

Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders
Lobe Sciences welcomes White House Executive Order supporting advancements in neurology and mental health treatments, focusing on scientific research and compound evaluation

Mental Health Neurology Thérapies Lobe Sciences White House Executive Order
BRIEF

published on 04/21/2026 at 12:05, 5 days 6 hours ago

Lobe Sciences Ltd. Partners with Massive Intelligence for Investor Relations

Investor Relations Biopharmaceuticals Corporate Communications Lobe Sciences Massive Intelligence
PRESS RELEASE

published on 04/21/2026 at 12:00, 5 days 6 hours ago

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services
Lobe Sciences engages Massive Intelligence for investor relations and corporate communications services. Massive Intelligence to provide promotional services via social media, email, and press releases

Investor Relations Biopharmaceutical Corporate Communications Lobe Sciences Massive Intelligence
BRIEF

published on 04/20/2026 at 12:05, 6 days 6 hours ago

Lobe Sciences Completes Private Placement and Provides Corporate Update

Private Placement Biopharmaceutical Investment Lobe Sciences Sickle Cell Treatment S-100 Development
PRESS RELEASE

published on 04/20/2026 at 12:00, 6 days 6 hours ago

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update
Lobe Sciences Ltd. announces closing of non-brokered private placement offering to advance S-100 drug candidate for sickle cell disease treatment

Private Placement Biopharmaceutical Sickle Cell Disease Lobe Sciences Ltd. S-100 Drug Candidate
BRIEF

published on 04/11/2026 at 02:05, 15 days 16 hours ago

Lobe Sciences Ltd. Announces Private Placement for $950,000

Private Placement Funding Canada Securities Laws Regulatory Approvals
PRESS RELEASE

published on 04/11/2026 at 02:00, 15 days 16 hours ago

Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Lobe Sciences Ltd. announces non-brokered private placement offering to raise approximately $950,000 for working capital and corporate expenses. Focus on neurology and psychiatry therapies

Private Placement Psychiatry Neurology Thérapies Lobe Sciences Ltd.
BRIEF

published on 03/25/2026 at 13:25, 1 month 1 day ago

Lobe Sciences Ltd. Enhances Financial Stability

Shareholder Value Debt Reduction Financial Stability Strategic Restructuring Subsidiary Model
PRESS RELEASE

published on 03/25/2026 at 13:20, 1 month 1 day ago

Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
Lobe Sciences Ltd. significantly improves financial position: liabilities down 81%, cash up 24x, net working capital up $6.1M, outstanding warrants down 70%, and strengthened the balance sheet and capital structure

Financial Position Balance Sheet Capital Structure Strategic Update Lobe Sciences Ltd.

1 2 ... 5

Accesswire

Published on 04/25/2026 at 03:10, 1 day 15 hours ago

BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 1 day 20 hours ago

Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:00, 1 day 20 hours ago

Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 2 days 3 hours ago

Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 2 days 3 hours ago

First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer

View all ACCESSWIRE

EQS Group

Published on 04/26/2026 at 10:20, 8 hours 12 minutes ago

EQS-Adhoc: Vitruvia Medical AG: Annual Results as of December 31, 2025
Published on 04/26/2026 at 09:05, 9 hours 28 minutes ago

Natural Expressions Unveils Performance 7: The Era of "Drop-and-Mow" Wireless Robotic Mowing Arrives in Europe
Published on 04/25/2026 at 16:25, 1 day 2 hours ago

Leading a New Era of Family Mobility! CHERY TIGGO V, the 3-in-1 Family Vehicle, Debuts at AutoChina2026
Published on 04/24/2026 at 22:43, 1 day 19 hours ago

EQS-Adhoc: Marley Spoon Group SE: Closing of the financing transaction in connection with the financial restructuring of its German subsidiary Marley Spoon SE with increased financing amou
Published on 04/24/2026 at 22:05, 1 day 20 hours ago

Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study

Les Echos

Published on 04/24/2026 at 17:45, 2 days ago

Share buyback for cancellation
Published on 04/24/2026 at 17:45, 2 days ago

Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 2 days 1 hour ago

Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 2 days 23 hours ago

Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
Published on 04/23/2026 at 18:18, 3 days ago

Aéroports de Paris SA - Sale by Groupe ADP of securities representing 3.4% with option to sell an additional 3.9% of GAL's equity share capital to GMR Group

View all LES ECHOS COMFI WIRE